← Eichor
Study identifier: NCT07219368 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

Condition: Healthy Volunteer  ·  Sponsor: Mirador Therapeutics, Inc.

PhasePhase 1
Planned participants72
Who can joinAll sexes, 19 Years to 55 Years
Healthy volunteersYes

About this study

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

This description comes directly from the study's public registry record.

Talk to the study team

Toll-Free Number  ·  844-206-4980  ·  clinicaltrials@miradortx.com

Always discuss trial participation with your own doctor first.

Locations (1)

Mirador Clinical Department, San Diego, California 92121San Diego, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07219368